Navigation Links
ViroPharma to Present at the Natixis Bleichroeder Conference
Date:10/3/2007

EXTON, Pa., Oct. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Michel de Rosen, president and chief executive officer of ViroPharma, will present at the Natixis Bleichroeder Conference at 10:30 A.M. ET on Monday, October 8, 2007. The conference is being held at the Carlton Hotel in New York.

ViroPharma's presentation will be webcast live for investors through http://www.viropharma.com and available through October 22, 2007.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ViroPharma Announces Presentation of Additional HCV-796 Data at Meeting of The European Association for the Study of the Liver
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, ... recognized for adherence to the highest standards of trauma, maternity, cancer and chronic ... center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the American ...
(Date:12/8/2016)... ... ... Vida Health, the digital health platform that pairs individuals with ... . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect Ventures. Vida ... are managing chronic conditions or simply want to improve their health. Canvas ...
(Date:12/8/2016)... ... ... Coppin Insurance Agency, an insurance and financial planning firm based in Lee ... is embarking on a charity drive with the goal of providing support and donations ... Bank of Southwest Florida works to provide fresh and nutritious food free of charge ...
Breaking Medicine News(10 mins):